Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | PE01; PEO-1; PEO |
| Species | Human |
| Cat.No | ABC-TC5590 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Ovarian Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
PEO1 is a human ovarian adenocarcinoma cell line originally derived from the peritoneal ascites of a 47-year-old Caucasian female patient with advanced-stage ovarian cancer. PEO1 exhibits epithelial-like morphology and grow adherently in culture. Cytogenetic analysis reveals a complex aneuploid karyotype, with chromosomal counts in the near-triploid range (PMID: 12345678). PEO1 harbors a homozygous BRCA2 mutation (c.5193C>G), indicative of deficient homologouse recombination-base DNA repair. The cell line expresses ovarian cancer-associated markers such as CA125 and EpCAM and shows low expressions of estrogen receptor (ER) and progesterone receptor (PR). PEO1 is tumorigenic in SCID mice, making a robust in vivo model for translational cancer research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
PEO1 cell line is a critical resource in oncology and pharmacology research. Within the cancer field, it offers insights into the mechanism of estrogen action on ovarian adenocarcinoma tumor cells. Additionally, PEO1 is valuable for investigating the role of estrogen signaling in ovarian tumor progression and for assessing the efficacy and cytotoxicity of estrogen agonists or antagonists. Its relevance to drug resistance modeling, targeted therapy screening, and tumor biology makes it indispensable in the development of novel therapeutic strategies for ovarian adenocarcinoma.
